Literature DB >> 30707500

Design, Synthesis, and Evaluation of Lipopeptide Conjugates of Mercaptoundecahydrododecaborate for Boron Neutron Capture Therapy.

Aoi Isono1, Mieko Tsuji1, Yu Sanada2, Akari Matsushita1, Shinichiro Masunaga2, Tasuku Hirayama1, Hideko Nagasawa1.   

Abstract

We developed new 10 B carriers for boron neutron capture therapy (BNCT) that can effectively transport and accumulate boron clusters into cells. These carriers consist of a lipopeptide, mercaptoundecahydrododecaborate (BSH), and a disulfide linker. The carriers were conceived according to the structure of pepducin, a membrane-penetrating lipopeptide targeting protease-activated receptor 1 (PAR1). To improve the membrane permeability of BSH, the structure was optimized using various lipopeptides possessing different peptides and lipid moieties. These synthesized lipopeptides were conjugated with BSH and evaluated for intracellular uptake using T98G glioblastoma cells. Among them, the most effectively incorporated and accumulated in the cells was compound 5 a, which contains a peptide of 13 residues derived from the intracellular third loop of PAR1 and a palmitoyl group. For further improvement of 10 B accumulation in cells, the introduction of an amine linker was investigated; intracellular uptake similar to that of 5 a was observed for compound 14, which has a piperazine linker. Both compounds 5 a and 14 showed a stronger radiosensitizing effect than BSH along on T98G cells under mixed-neutron beam irradiation. The results demonstrate that lipopeptide conjugation is effective for enhancing intracellular delivery and accumulation of BSH and improving the cytotoxic effect of BNCT.
© 2019 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  antitumor therapy; boron carriers; boron neutron capture therapy; membrane-permeable lipopeptides

Mesh:

Substances:

Year:  2019        PMID: 30707500     DOI: 10.1002/cmdc.201800793

Source DB:  PubMed          Journal:  ChemMedChem        ISSN: 1860-7179            Impact factor:   3.466


  5 in total

Review 1.  Theranostics in Boron Neutron Capture Therapy.

Authors:  Wolfgang A G Sauerwein; Lucie Sancey; Evamarie Hey-Hawkins; Martin Kellert; Luigi Panza; Daniela Imperio; Marcin Balcerzyk; Giovanna Rizzo; Elisa Scalco; Ken Herrmann; PierLuigi Mauri; Antonella De Palma; Andrea Wittig
Journal:  Life (Basel)       Date:  2021-04-10

2.  Ruthenium carboranyl complexes with 2,2'-bipyridine derivatives for potential bimodal therapy application.

Authors:  Ricardo G Teixeira; Fernanda Marques; M Paula Robalo; Xavier Fontrodona; M Helena Garcia; Simonetta Geninatti Crich; Clara Viñas; Andreia Valente
Journal:  RSC Adv       Date:  2020-04-23       Impact factor: 4.036

3.  Closo-Carboranyl- and Metallacarboranyl [1,2,3]triazolyl-Decorated Lapatinib-Scaffold for Cancer Therapy Combining Tyrosine Kinase Inhibition and Boron Neutron Capture Therapy.

Authors:  Marcos Couto; Catalina Alamón; María Fernanda García; Mariángeles Kovacs; Emiliano Trias; Susana Nievas; Emiliano Pozzi; Paula Curotto; Silvia Thorp; María Alejandra Dagrosa; Francesc Teixidor; Clara Viñas; Hugo Cerecetto
Journal:  Cells       Date:  2020-06-05       Impact factor: 6.600

Review 4.  Boron neutron capture therapy: Current status and future perspectives.

Authors:  Mayya Alexandrovna Dymova; Sergey Yurjevich Taskaev; Vladimir Alexandrovich Richter; Elena Vladimirovna Kuligina
Journal:  Cancer Commun (Lond)       Date:  2020-08-17

5.  Cobaltabis(dicarbollide) ([o-COSAN]-) as Multifunctional Chemotherapeutics: A Prospective Application in Boron Neutron Capture Therapy (BNCT) for Glioblastoma.

Authors:  Miquel Nuez-Martinez; Catarina I G Pinto; Joana F Guerreiro; Filipa Mendes; Fernanda Marques; Amanda Muñoz-Juan; Jewel Ann Maria Xavier; Anna Laromaine; Valeria Bitonto; Nicoletta Protti; Simonetta Geninatti Crich; Francesc Teixidor; Clara Viñas
Journal:  Cancers (Basel)       Date:  2021-12-19       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.